An important barrier for axon regeneration and recovery after traumatic spinal cord injury (SCI) is attributed to the scar that is formed at the lesion site. Here, we investigated the effect of mouse mast cell protease (mMCP) 6, a mast cell (MC)-specific tryptase, on scarring and functional recovery after a spinal cord hemisection injury. Functional recovery was significantly impaired in both MC-deficient and mMCP6 knockout (mMCP6 2/2 ) mice after SCI compared with wild-type control mice. This decrease in locomotor performance was associated with an increased lesion size and excessive scarring at the injury site. Axon growth-inhibitory chondroitin sulfate proteoglycans and the extracellular matrix components fibronectin, laminin, and collagen IV were significantly up-regulated in MC-deficient and mMCP6 2/2 mice, with an increase in scar volume between 23 and 32%. A degradation assay revealed that mMCP6 directly cleaves fibronectin and collagen IV in vitro. In addition, gene expression levels of the scar components fibronectin, aggrecan, and collagen IV were increased up to 6.8-fold in mMCP6
Traumatic spinal cord injury (SCI) is a devastating condition that results in irreversible locomotor, sensory, and autonomic dysfunctions for which currently no effective clinical treatment exists (1) . A major impediment for regenerative processes after injury to the CNS is attributed to the poor intrinsic growth potential of damaged axons and more importantly to the expression of inhibitory factors that are associated with the lesion scar (2, 3) . After injury, local and infiltrating cells (e.g., astrocytes, microglia, oligodendrocyte precursors, pericytes, meningeal fibroblasts) are activated and express extracellular matrix (ECM) molecules, which form a dense scar at the lesion site (4, 5) . This scar is characterized by the deposition of inhibitory chondroitin sulfate proteoglycans (CSPGs) in the perilesional area and the formation of a fibrous and basement membrane-rich compartment in the lesion center (6) (7) (8) (9) (10) (11) . The fibrotic scar consists of different matrix components that inhibit axon growth such as collagen IV, laminin, and fibronectin (12) (13) (14) . Although scarring is beneficial in the acute phase after injury where it is essential to regain tissue integrity and to limit secondary damage, it blocks regenerative processes at later times (5, 9, 15) . Together with other inhibitors (e.g., myelin debris), scar tissue is considered as the most important barrier for axon regeneration/sprouting and other recovery processes after SCI (3, 5) . Hence, understanding endogenous mechanisms that beneficially influence the injury-induced scar, is essential to therapeutically target the limited self-regeneration of the CNS (1) .
Mast cells (MCs) are multifunctional effector cells of the immune system that are characterized by electron-dense granules in their cytoplasm (16, 17) . In these granules, MCs store many preformed mediators, Abbreviations: BMS, Basso Mouse Scale; CBA, cytometric bead array; CCL2, C-C chemokine ligand 2; CSPG, chondroitin sulfate proteoglycan; CYCA, cyclophilin A; dpi, days postinjury; ECM, extracellular matrix; GFAP, glial fibrillary acidic protein; HMBS, hydroxymethylbilane synthase; MC, mast cell; mMCP, mouse mast cell protease; MCP-1, (continued on next page) including histamine, cytokines, and neutral MC-specific proteases such as tryptase among other factors (18, 19) . These mediators are released in the extracellular space in response to a wide range of (patho)physiologic stimuli (20) . MCs are best known for their role in type I hypersensitivity reactions, but they also have important functions in innate and adaptive immune responses (21) . Considerable progress has been made in elucidating the crucial role of MCs in the pathology of inflammatory CNS disorders, such as multiple sclerosis and stroke (reviewed by Nelissen et al.) (22) . Apart from their proinflammatory and mainly detrimental role in multiple contexts (23) (24) (25) , MCs also exert a number of important beneficial functions. We previously reported a favorable role of MCs after traumatic CNS injuries. Experiments in knockout mice indicate that MCs support neuronal survival and functional recovery after CNS injury (26, 27) . In particular, MCs appear to be protective in neuroregenerative processes following CNS trauma, due to their ability to degrade inflammation-associated cytokines such as C-C chemokine ligand 2 (CCL2)/ monocyte chemoattractant protein-1 (MCP-1), and IL-6, and thereby temper detrimental inflammatory processes (27) . These processes are at least partly mediated via mouse mast cell protease (mMCP) 4, an MC-specific chymase. Apart from their immunomodulatory role, MCs also play an important role in other wound healing processes via their specific proteases, especially in ECM remodeling (28, 29) . The most abundant protease stored and secreted by human MCs is b-tryptase, a serine protease with trypsin-like cleavage specificity, which corresponds to mMCP6 in mice (30, 31) . Although mMCP6 is known to be a potent inflammatory mediator, it also plays a key role in ECM remodeling, either directly or indirectly by activating other ECM-degrading enzymes (e.g., matrix metalloproteinases, plasminogen activators) (32) (33) (34) .
In this study, we show that functional recovery is impaired in both MC-deficient and mMCP6 knockout mice after a spinal cord hemisection injury. In contrast to mMCP4, which degrades important inflammatory mediators (27) , mMCP6 leaves the inflammation-associated cytokine milieu intact, suggesting a different mechanism via which mMCP6 may exert beneficial effects after injury. Therefore, we hypothesized that the beneficial effects of endogenous mMCP6 after SCI were mediated via ECM-remodeling. Indeed, the decline in motor function in both MC-deficient and mMCP6 knockout mice was associated with increased scarring levels at the lesion site. We provide evidence that mMCP6 is involved in scar remodeling after SCI by indirect cleavage of scar components and by altering the gene expression profile of these factors. In conclusion, these data indicate that endogenous mMCP6 is an important factor in recovery processes after SCI.
MATERIALS AND METHODS Animals
All in vivo experiments were performed using 10-to 12-wk-old female mice. MC-deficient Kit W-sh/W-sh and their wild-type (WT) littermates (The Jackson Laboratory, Sacramento, CA, USA) were used to investigate MC-specific functions. These Kit W-sh/W-sh mice carry a W-sash (W-sh) inversion mutation, which results in reduced c-kit tyrosine kinase-dependent signaling and therefore MC deficiency (35) . We also used mMCP6 knockout (mMCP6 2/2 ) mice, which were backcrossed for 10 generations onto the C57BL/6 background (36) . WT C57BL/6j mice (Janvier, Le Genest-Saint-Isle, France) were used as controls. These mMCP6 2/2 mice were kindly provided by Dr. David Lee (Novartis Pharma, Basel, Switzerland) and Dr. Peter Nigrovic (Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA).
Mice were housed in a conventional animal facility at Hasselt University under standardized conditions [i.e., in a temperature-controlled room (20 6 3°C) on a 12 h light-dark schedule and with food and water ad libitum]. All experiments were approved by the Hasselt University Ethics Committee and they were performed according to the guidelines described in Directive 2010/63/EU on the protection of animals used for scientific purposes.
Experimental SCI
A hemisection injury was performed as previously described (27, 37) . Briefly, mice were anesthetized by intraperitoneal injection of ketamine (100 mg/kg, Ketalar, Pfizer, Elsene, Belgium) and xylazine (12 mg/kg, Rompun; Bayer, Diegem, Belgium), and a partial laminectomy was performed at thoracic level 8 to expose the spinal cord. A bilateral hemisection injury of the spinal cord was induced by using iridectomy scissors to transect left and right dorsal funiculus, the dorsal horns, and additionally the ventral funiculus. This T-cut hemisection results in a complete transection of the dorsomedial and ventral corticospinal tract and it also impairs several other descending and ascending tracts (e.g., rubrospinal tract). Afterward, muscles were sutured and the back skin was closed with wound clips (Autoclip; Clay-Adams Co., Inc., Becton-Dickinson, Erembodegem, Belgium). The following drugs were given after the operation: glucose solution (20%) to compensate for any blood loss during surgery, buprenorphine (0.1 mg/kg, Temgesic; Schering Plough, Houten, The Netherlands) as a postoperative pain treatment and an antisedative (0.5 mg/kg, Antisedan; Orion Pharma, Mechelen, Belgium) to improve recovery after the surgery. All mice were placed in a temperature-controlled chamber (33°C) until thermoregulation was established. Bladders were emptied manually until the micturition reflex returned spontaneously. To standardize our model, all operations were performed by a trained experimenter, and all experiments within the study were executed by the same person. Mice were randomly operated (either control or test group) and blinded to the person performing the surgery. All mice were operated in the same way, and mice that displayed abnormalities during the surgery were excluded from the study (e.g., substantial variations in morphology of the spinal blood vessels, unusual strong bleeding, abnormal response to the anesthesia). Mice that display abnormalities (e.g., pain behavior, infections) or dramatically lose weight (.10% percent of body weight) during the experiment would have been excluded from the study. However, none of the mice showed these symptoms.
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Assessment of locomotor recovery
Locomotor recovery of the animals was determined by using the Basso Mouse Scale (BMS) (38, 39) . This BMS is a 10-point locomotor rating scale (9 = normal locomotion; 0 = complete hind limb paralysis), in which mice are scored by an investigator blinded to the experimental groups and which is based on hind limb movements made in an open field during a 4-min interval. During the first week after injury, mice were scored daily and from the start of the second week until the end of the observation period (27 d postinjury [dpi]), mice were examined every second day. The following exclusion criteria were applied: mice that still had a BMS score of 0 at the end of the observation period (27 dpi) or mice that had a BMS score of $2 immediately after the operations were excluded from the study.
Cytometric bead array-cytokine/chemokine protein levels Cytokine/chemokine protein levels were determined locally in the injured spinal cord in WT control mice and mMCP6 2/2 mice at 2 dpi and 7 dpi. Healthy control mice that did not undergo surgery were also included in the analysis for both groups. At these selected time points, mice received an overdose of pentobarbital (100 mg/kg, Nembutal; Ceva, Brussels, Belgium) and were transcardially perfused with Ringer solution (1.98 mM NaCl, 44 mM KCl, 27 mM CaCl 2 , 5.8 mM NaHCO 3 , 70 mM NaNO 2 and 280 mM phenol red in MilliQ) supplemented with heparin (Leo Pharma, Lier, Belgium). Standardized areas of spinal cord tissue (3 mm cranial and 3 mm caudal to the lesion center) were collected and proteins were extracted using the PARIS Kit (Life Technologies, Merelbeke, Belgium), according to the manufacturer's instructions. Total protein levels were determined using the BCA Protein Assay Kit (Thermo Fisher Scientific, Erembodegem, Belgium), according to the manufacturer's instructions. Protein expression levels of IL-2, IL-4, IL-10, IL-17a, IL-1b, IL-6, IFN-g, TNF-a, and CCL2/ MCP-1 were quantitatively determined in spinal cord homogenates via flow cytometry analysis using the mouse Cytometric Bead Array (CBA) T h 1/T h 2/T h 17 kit and specific mouse Flex set systems (BD Biosciences, Erembodegem, Belgium), according to the manufacturer's instructions. Briefly, serial dilutions of the standard were prepared and samples were incubated with capture beads at room temperature (RT) for 1 h. Afterward, detection beads were added and samples were incubated for another hour at RT. Finally, all samples were washed with wash buffer and analysis were performed using FACS Array Bioanalyzer (BD Biosciences) and FCAP software (Soft Flow, Inc., St. Louis Park, MN, USA).
Immunohistochemistry
At 28 dpi, mice received an overdose of Nembutal and they were transcardially perfused with Ringer solution containing heparin, followed by 4% paraformaldehyde in PBS (pH 7.4). Next, 14 mm thick sagittal tissue sections were cut and immunohistochemical stainings were performed. Spinal cord sections were blocked with 10% normal goat serum and permeabilized with 0.05% Triton X-100 in PBS for 30 min at RT. Then, the following primary antibodies were incubated overnight at 4°C in a humidified chamber: mouse anti-glial fibrillary acidic protein (GFAP) (1:500; SigmaAldrich, Bornem, Belgium), rabbit anti-laminin 1a (1:200; Abcam, Cambridge, United Kingdom), rabbit anti-fibronectin (1:200; Abcam), rabbit anti-collagen type IV (1:200; Abcam) and mouse anti-CSPGs (1:200; Sigma-Aldrich). Following repeated washing steps with PBS, spinal cord sections were incubated with Alexa-labeled secondary antibodies for 1 h at RT, namely goat anti-mouse IgG Alexa 555, goat anti-rabbit Alexa 488, goat anti-rat Alexa 488, and goat anti-mouse IgM Alexa 555 (1:250; all secondary antibodies were obtained from Life Technologies). Isotype control stainings were included as a negative control to measure the level of nonspecific background signal caused by the primary antibodies (data not shown). Additionally, also the specificity of the secondary antibodies was verified by including control stainings in which the primary antibody was omitted (data not shown). A DAPI (Life Technologies) counterstain was performed to reveal cellular nuclei whereafter sections were mounted. Images were taken with an Eclipse 80i microscope and a digital sight camera DS2MBWc (Nikon, Amstelveen, The Netherlands).
Quantitative image analysis
Quantitative image analysis was performed on original unmodified photos using the ImageJ open source software (National Institutes of Health, Bethesda, MD, USA). The investigator was blinded to the origin of the samples and all images were randomized before the analyses were performed. For standardization, analyses were performed on 5-8 spinal cord sections (per mouse) representing the lesion area (i.e., the lesion epicenter as well as consecutive sagittal sections, as previously described) (22) . Spinal cord lesion areas are subdivided in different regions (i.e., the lesion epicenter, the perilesional area, and the surrounding tissue). Lesion size was evaluated by delineating the area in which there was no GFAP expression (i.e., the lesion center). Quantification of astrogliosis (GFAP expression) was performed in the perilesional area via intensity analysis of GFAP immunoreactivity within square areas of 100 3 100 mm, extending from 600 mm cranial to 600 mm caudal from the lesion border. Both the scar positive area and immunoreactivity for the following scar components was determined in the lesion center, namely fibronectin, laminin, and collagen IV. To evaluate the expression of inhibitory CSPGs, intensity of CSPG-immunoreactivity was measured perilesionally in a well-defined area surrounding the lesion center (;200 mm lesion border). To maximize image readability, the contrast and brightness of the stainings was enhanced equally in the corresponding groups. Furthermore, the tissue section borders were highlighted using a white line for clarity.
Production recombinant mMCP6
Expression and purification recombinant mMCP6
Recombinant mMCP6 was expressed in a eukaryote expression system using the human endothelial kidney cell line, 293 EBNA, as previously described (40, 41) . Transfection of these 293 EBNA cells with an mMCP6-containing pCEP-Pu2 vector (Supplemental Fig. 1A ) was performed in the laboratory of Dr. Gunnar Pejler. Recombinant mMCP6 was produced as a fusion protein, which consisted of an N-terminal BM40 signal peptide (to ensure secretion of the fusion protein into the cell culture medium), followed by a His 6 (Histidine)-tag and an enterokinase (EK) susceptible cleavage site (Asp-Asp-Asp-Asp-Lys), substituting for the native activation peptide (Supplemental Fig. 1A ). These transfected 293 EBNA cells were cultured in DMEM (Life Technologies) supplemented with 10% fetal bovine serum (Life Technologies), 1% penicillin, and streptomycin (Life Technologies), 100 mg/ml gentamicin (Sigma-Aldrich) and 5 mg/ml puromycin (Sigma-Aldrich) (Supplemental Fig. 1B) . After culturing, conditioned medium containing the fusion protein was centrifuged (418 g, 10 min) to remove cellular debris, and the supernatant was stored at 220°C until further processing. Recombinant BM40-His 6 -EK-mMCP6 was purified from the conditioned medium using Ni-NTA Sepharose beads (Sepharose; IBA GmbH, Goettingen, Germany) that bind the His 6 -tag in the fusion protein. Ni 2+ beads were added to the conditioned medium and the mixture was rotated at 64°C for 6 h. Afterward, beads were collected via centrifugation (290 g, 5 min) and washed with PBS (pH 7.0), 1 M NaCl, and 0.1% Tween 20 until impurities were undetectable in the washing fractions, as evaluated by SDS-PAGE analysis. Briefly, purified samples were mixed with loading buffer containing 5% b-mercaptoethanol (Fluka Biochemika, Buchs, Switzerland), heated for 5 min at 95°C, and denaturated proteins were separated on a 12% polyacrylamide gel (100 V, 1 h). After electrophoresis, separated proteins were visualized in the gel using a Coomassie brilliant staining (PhastGelBlue R; GE Healthcare, Diegem, Belgium). When impurities were undetectable, imidazole (200 mM in PBS; pH 7.0) was used to elute the bound mMCP6 fusion protein from the beads. Using a calculated molar extinction coefficient of 68.810 M 21 cm
21
(Lambert-Beer Law), the concentration of mMCP6 was determined by measuring the absorbance at 280 nm (A280) on a spectrophotometer (Nanodrop 2000C; Thermo Fisher Scientific).
Activation recombinant mMCP6
To remove the BM40-His 6 -EK propeptide, the purified fusion protein was incubated with EK (Roche Diagnostics, Almere, The Netherlands) at a BM40-His 6 -EK-mMCP6/EK ratio (w/w) of 500: 1 in PBS (pH 6.0) overnight at 37°C. EK-cleavage efficiency of the fusion protein was determined using SDS-PAGE and a Coomassie staining as previously described. An EK-removal kit (SigmaAldrich) was used to discard any remaining EK and microdialysis in PBS (pH 6.0) was performed to remove imidazole (Slide-A-Lyzer Dialysis, Cassette G2 10K; Thermo Fisher Scientific). Tryptase activity was then determined using the chromogenic peptide S-2288 (H-D-Ile-Pro-Arg-pNA; Instrumentation Laboratory, Zaventem, Belgium), which is a substrate of mMCP6. Briefly, EK-cleaved mMCP6 (500 ng) was preincubated (30 min at 37°C) with different concentrations of pig mucosal heparin (MW 17-19 kDa; H5515; Sigma-Aldrich) and the proteolytic activity was measured after adding the chromogenic substrate S-2288 (2 mM). Also a condition without heparin was included as a control. Differences in absorbance were monitored at 37°C and a wavelength of 410 nm using a spectrophotometer (Fluostar optima; BMG Labtech, Offenburg, Germany). Protease activities were determined, averaging 3 measurements, and results are shown as means 6 SEM. Recombinant mMCP6 was inactivated by heating at 100°C for 10 min to generate a proteolytically inactive vehicle (Supplemental Fig. 2 ).
Immunofluorescence transfected human endothelial kidney cells
Transfected 293 EBNA cells were grown on glass coverslips in the culturing conditions as described previously. Images of cultured cells were taken using an inverted phase-contrast microscope (Eclipse TS100; Nikon) equipped with a ProgRes C3 digital camera (Jenoptik AG, Jena, Germany). After confluence (;90%), cells were fixed for 10 min in 4% paraformaldehyde in PBS (pH 7.4). For immunohistochemical stainings, cells were washed with PBS, blocked with 10% normal goat serum, and permeabilized with 0.05% Triton X-100 in PBS for 30 min at RT. The following primary antibodies were incubated overnight at 4°C: mouse anti-penta-His (1:200; Qiagen, Venlo, The Netherlands) and rabbit anti-mMCP6 (1:200, produced in the lab of Dr. Gunnar Pejler) (42) . Following repeated washing steps with PBS, cells were incubated with Alexa-labeled secondary antibodies for 1 h at RT, namely goat anti-mouse IgG Alexa 555 and goat anti-rabbit Alexa 488 (1:250; Life Technologies). Following removal of unbound antibodies, a DAPI (Life Technologies) counterstain was performed and glass coverslips were mounted on microscope slides. Images were taken with a fluorescence microscope equipped with a DS-2MBWcdigital sight camera (Eclipse 80i; Nikon).
Culture of bone marrow-derived MCs and collection of MC degranulate
Murine MCs were obtained as previously described (43), by culturing primary bone marrow cells isolated from the femurs and tibia of WT C57BL/6 mice or mMCP6 2/2 mice in IMDM with L-glutamine (Life Technologies) supplemented with 10% fetal bovine serum (Life Technologies), 1% penicillin and streptomycin (Life Technologies), 0.002% a-monothioglycerol (Sigma-Aldrich) and 10 ng/ml recombinant mouse IL-3 (Life Technologies). These bone marrow-derived MC cultures were used after 4-5 wk when they consisted of 695% MCs as evaluated by surface expression of Fc-e receptor I (eBioscience, Vienna, Austria) by flow cytometry analysis (data not shown). Mature MCs were collected (5 3 10 4 cells), washed and stimulated for 30 min at 37°C and 5% CO 2 with 1 mM ionomycin (Sigma-Aldrich) in 100 ml Tyrode's buffer (130 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 1.4 mM CaCl 2 , 10 mM HEPES, 5.6 mM glucose and 0.01% BSA in MilliQ). MC degranulate was then collected and used for the degradation assays as described below.
mMCP6 protein expression and tryptase activity measurement in MC degranulate
As a control, tryptase activity and mMCP6 protein expression were both determined in MC WT degranulate and MC mMCP6 2/2 degranulate. Tryptase activity was determined as described above using the chromogenic substrate S-2288. Also mMCP6 protein expression was examined via SDS-PAGE and Western blot analysis. Briefly, samples were denaturated and separated on a 12% polyacrylamide gel containing Tris-glycine and transferred onto a polyvinylidene difluoride (PVDF) membrane. This membrane was blocked in 5% nonfat powdered milk in Tris-buffered salineTween 20 (0.1%) (TBST) for 1 h and probed overnight at 4°C with a rat anti-mMCP6 antibody (1:500; R&D Systems, Abingdon, United Kingdom) and a mouse anti-b-actin antibody (1:5000; Santa Cruz Biotechnology, Heidelberg, Germany), which was included as a loading control. Afterward, the PVDF membrane was washed with TBST and incubated with a goat anti-rat and goat anti-mouse horseradish peroxidase-labeled secondary antibody (dilution 1:5000; all secondary antibodies obtained from Dako, Heverlee, Leuven). An ECL Plus detection kit (Thermo Fisher Scientific) was used and the generated chemiluminescent signal was detected by a luminescent image analyzer (ImageQuant LAS 4000 mini; GE Healthcare).
In vitro degradation assays

Cytokines/chemokines
Murine recombinant IL-1b, IL-4, IL-6, IL-10, TNF-a, and CCL2/ MCP-1 (400 ng; all cytokines were obtained from Tebu-bio, Boechout, Belgium) were incubated for 48 h at 37°C with recombinant mMCP6 (40 ng) or an inactive vehicle (40 ng). After incubation, samples were mixed with Novex Tricine SDS Sample buffer and NuPage Reducing Agent (Life Technologies) and the cleaved fragments were identified using Tris-tricine SDS-PAGE on 10% Novex Tricine Gels and a SilverXpress Silver Staining Kit (Life Technologies). Quantification of the protein bands was performed using an intensity analysis in the ImageJ software. To limit variations between independent experiments, due to differences in densitometric measurements, each control condition per experiment was set at 100% and therefore lacking a standard error bar.
ECM/scar components
Murine recombinant fibronectin (1 mg; Abcam), laminin (0.5 mg; Millipore, Overijse, Belgium), collagen IV (2 mg; R&D Systems), or a CSPG-mix (CC117, 2 mg; Millipore) were incubated with recombinant mMCP6 (5 mg) or an inactive vehicle (5 mg) for 1 h at 37°C. In another approach, we incubated these ECM components with 20 ml MilliQ or 20 ml degranulate obtained from either WT or mMCP6 2/2 MCs for 48 h at 37°C. Incubations for collagen IV were performed at 4°C to prevent polymerization. After incubation, samples were mixed with reducing sample buffer and the cleaved fragments were identified via SDS-PAGE and Western blot analysis. Briefly, sample buffer containing 5% b-mercaptoethanol (Fluka Biochemika) was added and the incubation mixture was denaturated at 95°C for 5 min. Western blotting for collagen IV was performed under native conditions (no denaturation with b-mercaptoethanol). Protein samples were separated on 7.5% polyacrylamide gels, containing Tris-glycine and transferred onto PVDF membranes. Membranes were blocked in 5% nonfat powdered milk in TBST for 1 h and probed overnight at 4°C with one of the following primary antibodies: antifibronectin (1:1000; Santa Cruz Biotechnology), anti-collagen type IV (1:2000; Abcam), anti-laminin (1:1000; Abcam), or antiCSPGs (1:1000, CS56; Sigma-Aldrich). Next, membranes were washed with TBST and incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies: goat antimouse IgM and goat anti-rabbit (dilution 1:5000; all secondary antibodies obtained from Dako). An ECL Plus detection kit (Thermo Fisher Scientific) was used and the generated chemiluminescent signal was detected using a luminescent image analyzer (ImageQuant LAS 4000 mini, GE Healthcare). Densitometry of the protein bands that correspond with the known molecular weight of the ECM components was quantified via the ImageQuant TL software. As described above, each control condition per experiment was set at 100% to avoid artifacts.
RNA extraction and quantitative PCR analysis
mRNA expression levels of glial scar-associated components were investigated at different phases after SCI, namely the acute phase (2 dpi), the subacute phase (7 dpi), and finally the early stage of the chronic remodeling phase (28 dpi). At the selected time points, WT C57BL/6 and mMCP6 2/2 mice were transcardially perfused with Ringer solution as previously described. Healthy control mice that did not undergo surgery were also included in the analysis. Standardized areas of spinal cord tissue (3 mm cranial and 3 mm caudal to the lesion center) were collected and mRNA was extracted using the Paris Kit (Life Technologies), according to the manufacturer's instructions with minor modifications. An additional incubation step with chloroform was performed to remove fat/cholesterol from the spinal cords, which improves RNA extraction. Chloroform (VWR, Haasrode, Belgium) was mixed with spinal cord homogenates (volume ratio 1: 1) for 3 min at RT and supernatant was collected after centrifugation (12,000 g for 15 min). After reverse transcription to cDNA (VWR), a quantitative PCR was conducted on a StepOnePlus detection system (Applied Biosystems, Gaasbeek, Belgium) using universal cycling conditions (20 s at 95°C, 40 cycles of 3 s at 95°C and 30 s at 60°C). The reaction mixture contained fast SYBR Green master mix (Applied Biosystems), 10 mM of forward and reverse primers (Eurogentec, Seraing, Belgium), RNase free water, and 8 ng template cDNA in a total reaction volume of 10 ml. The following primer sequences were used: GFAP (Gfap): forward 5-TCTCCA-ACCTCCAGATCCGA-3 and reverse 5-CTGGTGAGCCTGTATTGGGA-3 (113 bp); fibronectin 1 (Fn1): forward 5-ATGTGGACCCCTCCTGATAGT-3 and reverse 5-GCCC-AGTGATTTCAGCAAAGG-3 (124 bp); collagen type IV a I (Col4a1): forward 5-AACAAC-TCTGCAACTTCGC-3 and reverse 5-CTTCACAAACCGCACACCTG-3 (136 bp); laminin a 1 (Lama1): forward 5-GGCGACAACATGCGCGG-3 and reverse 5-GAAT-GGCAGGGA-ACAAGCCTC-3 (109 bp); aggrecan (Acan): forward 5-GTCGCTCCCCA-ACTATCCAG-3 and reverse 5-AAAGTCCAGGGTGTAGCGTG-3 (193 bp); neurocan (Ncan): forward 5-GCACAGAA-GTGAGATCAGTGAGA-3 and reverse 5-GCACCATCTTGGTTCAGG-CA-3 (114 bp), and brevican (Bcan): forward 5-TGCCGAAGACCTAAATGGAGA-3 and reverse 5-CACGTTCCAG-ACAGTAGTCCC-3 (89 bp). Relative quantification of gene expression was accomplished by using the 2 -DDCT method. Data were normalized with the most stable reference genes, as previously described (44), and expression levels were converted to fold change values vs. the WT control condition. GeNorm software identified hydroxymethylbilane synthase (HMBS), cyclophilin A (CYCA), and tyrosine 3-monooxygenase/ tryptophan 5-monooxygenase activation protein z (YWHAZ) as the most stable reference genes. The following primers were used: (Hmbs): forward 5-TGCCGAAGACCTAAATGGAGA-3 and reverse 5-CACGT-TCCAGACAGTAGTCCC-3 (108 bp), (Ccna2): forward 5-TGCCGAAGACCTAAATGGAGA-3 and reverse 5-CACGTTCCAGACAGTAGTCCC-3 (149 bp), and (Ywhaz): forward 5-TGCCGAAG-ACCTAAATGGAGA-3 and reverse 5-CACGTTCCAGACAGTAGTCCC-3 (168 bp). Primers were designed using Primer-Express (http://www.ncbi.nlm.nih.gov/tools/ primer-blast).
Statistical analysis
All statistical analyses were performed using GraphPad Prism 5.01 software (GraphPad Software, Inc., La Jolla, CA, USA). Data sets were analyzed for normal distribution using the D'Agostino-Pearson normality test. Functional recovery in vivo and histologic analyses of the astrogliosis were statistically analyzed using 2-way ANOVA for repeated measurements with a Bonferroni post hoc test for multiple comparisons. All other differences between 2 groups were evaluated using the nonparametric Mann-Whitney U test. In vitro degradation assays were analyzed with a 1-way ANOVA to compare multiple groups followed by a Tukey post hoc test. Quantitative PCR data were analyzed using 2-way ANOVA with a Bonferroni post hoc test. Data were presented as means 6 SEM. Differences were considered statistically significant when P , 0.05.
RESULTS
Impaired functional recovery in MC-deficient and mMCP6 knockout mice after a spinal cord hemisection injury
To determine the effect of MCs on functional recovery after SCI, we performed an in vivo experiment in which MC-deficient Kit W-sh/W-sh mice and WT Kit +/+ mice were subjected to a dorsal T-cut hemisection. Both control and MC-deficient mice experienced complete hind limb paralysis immediately after injury, and mice in both groups gradually improved in time. However, compared with WT Kit +/+ mice, recovery of locomotor function was significantly decreased from d 5 onward until the end of the observation period in MC-deficient mice (Fig. 1A) . Individual BMS scores at 27 dpi are shown in Fig. 1B . As a next step, we investigated whether MCs exert their mMCP6 DEFICIENCY IMPAIRS RECOVERY AFTER SCIbeneficial effect on functional recovery after SCI via mMCP6. Therefore, we subjected mMCP6 2/2 mice and their corresponding WT controls to a spinal cord hemisection injury. Both WT and mMCP6 2/2 mice experienced complete hind limb paralysis immediately after injury. Although mice in both groups improved in time, locomotor function was significantly impaired in mMCP6 2/2 mice from d 5 onward until the end of the observation period compared with WT control mice (Fig. 1C) . Individual BMS scores at 27 dpi are shown in Fig. 1D .
Absence of mMCP6 did not change inflammatory cytokine levels after injury
Traumatic SCI is associated with the activation and infiltration of immune cells and their secretion of inflammatory mediators (cytokines and chemokines) at the lesion site (45) (46) (47) . To unravel whether the absence of mMCP6 also influenced these inflammatory processes, we performed a CBA analysis to compare cytokine/chemokine levels between WT and mMCP6 2/2 mice in the acute-subacute phase after SCI. Protein levels of the anti-inflammatory cytokines IL-4 and IL-10 were not increased in both WT and mMCP6 2/2 mice after injury compared with uninjured mice (Fig. 2A, B) . Furthermore, IL-4 protein levels were comparable between WT and mMCP6 2/2 mice after SCI ( Fig. 2A) . IL-10 protein levels were significantly higher in uninjured mMCP6 2/2 mice compared with uninjured WT mice; however, after injury, the difference between the groups was no longer statistically significant anymore (Fig. 2B) . Protein levels of the proinflammatory cytokine IL-6 were significantly up-regulated in WT and mMCP6
mice at 2 dpi and 7 dpi compared with uninjured mice (Fig. 2C) . However, no difference in IL-6 was observed between the WT and mMCP6 2/2 group. TNF-a protein levels were not increased after injury in WT and mMCP6 2/2 mice compared with uninjured mice, and there was no difference between the groups (Fig. 2D) . In contrast, CCL2/MCP-1 protein levels were significantly elevated in both groups after injury and at 7 dpi, these levels were significantly higher in mMCP6 2/2 mice compared with WT mice (Fig. 2E) . IL-1b protein levels were very low and mostly undetectable (data not shown). IL-2, IFNg, and IL-17a protein levels were also not increased after injury, and no difference was observed between the groups (data not shown). These data show that endogenous mMCP6 does not influence local cytokine protein levels after SCI. To further analyze these in vivo findings, we showed in an in vitro degradation assay that these inflammation-associated factors are not a substrate of mMCP6 (Fig. 2F-M) . Recombinant CCL2/MCP-1, IL-6, TNF-a, IL-4, IL-10, as well as IL-1b protein were incubated for 48 h in the presence of recombinant mMCP6 or a proteolytically inactive vehicle. SDS-PAGE and intensity analysis of the corresponding bands showed that only CCL2/MCP-1 was directly cleaved by mMCP6 (Fig. 2F, H) . IL-4, IL-10, IL-1b, IL-6, and TNF-a were not cleaved by recombinant mMCP6 in vitro (Fig. 2F, G, I-M) . Figure 2. Absence of endogenous mMCP6 did not change cytokine levels after SCI. CBA analysis was performed to compare cytokine/chemokine levels between healthy control mice (uninjured) and injured WT and mMCP6 2/2 mice that were sacrificed (continued on next page)
mMCP6 DEFICIENCY IMPAIRS RECOVERY AFTER SCI
Increased scarring response in MC-deficient mice after SCI
MCs play an important role in wound healing and ECM remodeling (28) . Therefore, we investigated whether the glial and fibrous scarring response was changed in MC-deficient mice compared with WT mice after SCI. A significant increase in lesion size (defined as the GFAPnegative area) was observed in MC-deficient Kit W-sh/W-sh mice compared with WT Kit +/+ mice at 28 dpi (Fig. 3Ai, Aii,  B) . Astrogliosis was determined by measuring GFAP intensity in the perilesional area in squares of 100 3 100 mm (white boxes in Fig. 3Ai, ii) , extending 600 mm cranial to 600 mm caudal from the lesion border. GFAP intensity peaked in both WT and Kit W-sh/W-sh mice at the lesion border and decreased further caudally and cranially from the lesion site (Fig. 3Ai, ii, C) . No difference in astrogliosis was observed between MC-deficient mice and control mice at 28 dpi (Fig. 3C) . Furthermore, we focused on 4 key components of the scar that accumulate at the lesion site after SCI and inhibit axon growth: CSPGs in the perilesional area (5, 7) and fibronectin, laminin, and collagen IV at the lesion center (9, 14, 48) . The intensity of axon-growth inhibitory CSPGs was analyzed in a well-defined area around the lesion center (white encircled area in Fig. 3Aiii, iv) . Immunoreactivity for CSPGs was significantly higher in the perilesional area in MC-deficient mice compared with WT Kit +/+ mice at 28 dpi (Fig. 3Aiii, Aiv, D) . Both the area and immunoreactivity of fibronectin were significantly increased at the lesion site in MC-deficient mice compared with WT mice (Fig. 4Ai, Aii, B, E) . In addition, the scar area and immunoreactivity of the basement membrane components laminin (Fig. 4Aiii , Aiv, C, F) and collagen IV (Fig.  4Av , Avi, D, G) were significantly increased in MC-deficient mice after SCI.
Increased scarring response in mMCP6 knockout mice after SCI As a next step, we investigated whether the reduced functional recovery in mMCP6 2/2 mice was associated with changes in glial and fibrous scarring. We found a significantly increased lesion size in mMCP6 2/2 mice compared with their corresponding controls after SCI (Fig.  5Ai, Aii, B) . GFAP intensity peaked in both WT and mMCP6 2/2 mice around the lesion border and decreased further caudally and cranially from the lesion site (Fig. 5Ai, Aii, C) . No difference in astrogliosis was observed between the 2 groups at 28 dpi (Fig. 5C) . Immunoreactivity of axon-growth inhibitory CSPGs was significantly upregulated in the perilesional area in mMCP6 2/2 mice compared with WT mice after SCI (Fig. 5Aiii, Aiv, D) . The fibronectin + scar area in mMCP6 2/2 mice was significantly enlarged compared with WT mice (Fig. 6Ai, Aii, B) whereas immunoreactivity for fibronectin at the lesion center was comparable between the groups (Fig. 6Ai, Aii, E) . Image analysis showed that the scar area of the basement membrane components, laminin (Fig. 6Aiii, Aiv, C) , and collagen IV (Fig. 6Av, Avi, D) was significantly enlarged in mMCP6 2/2 mice compared with WT mice. Immunoreactivity for laminin was also significantly higher at the lesion center in mMCP6 2/2 mice compared with the WT group (Fig. 6Aiii, Aiv, F) . No difference in intensity of collagen IV was observed between the 2 experimental groups after SCI (Fig. 6Av, Avi, G) .
mMCP6 degrades scar-associated ECM components in vitro
Using an in vitro degradation assay, we determined which scar-associated ECM components may be substrates of mMCP6. Recombinant fibronectin, laminin, collagen IV, or a mix of important axon-growth inhibitory CSPGs were incubated with recombinant mMCP6 or a proteolytically inactive vehicle (Supplemental Fig. 2 ) and with degranulate derived from MCs obtained from either WT C57BL/6 mice or mMCP6 2/2 mice. MMCP6 protein expression and tryptase activity were completely absent in MC mMCP6 2/2 degranulate compared with MC WT degranulate (Supplemental Fig. 3A, B) . Protein cleavage was analyzed via Western blot analysis. We did not observe any cleavage of CSPGs by recombinant mMCP6, MC WT , or MC mMCP6 2/2 degranulate (Fig. 7A, B) . In contrast, a strong cleavage of fibronectin was found after incubation with recombinant mMCP6. Fibronectin is visible via Western blot analysis as a 262 kDa protein band, which almost completely disappeared after incubation with recombinant mMCP6 compared with the control conditions (Fig. 7C, green box) . Furthermore, cleavage fragments also became visible at lower molecular weight levels after incubation with at 2 dpi and 7 dpi. A, B) Protein levels of the anti-inflammatory cytokines IL-4 (A) and IL-10 (B) in both WT and mMCP6 2/2 mice were not increased after injury. IL-4 protein levels were comparable between both groups. IL-10 protein levels were significantly higher in uninjured mMCP6 2/2 mice compared with uninjured WT mice, but after injury the difference between the groups was no longer statistically significant. C ) IL-6 protein levels were significantly increased in both WT and mMCP6 2/2 mice after injury, but no difference was observed between the groups. D) TNF-a protein levels were not increased in WT and mMCP6 2/2 mice after injury compared with uninjured mice and there was no difference between the groups. E ) CCL2/MCP-1 protein levels were significantly increased in both groups after injury, and at 7 dpi these levels were significantly increased in mMCP6 2/2 mice compared with WT mice. Data are presented as means 6 SEM. n = 4-6/group. nd, not detected; ns, not significant. Additionally, a degradation assay showed that mMCP6 does not cleave cytokines in vitro. Recombinant IL-4, IL-10, IL1b, TNF-a, CCL2/MCP-1, and IL-6 were incubated with recombinant mMCP6 or an inactive vehicle and protein degradation was analyzed via SDS-PAGE and silver stain. Intensity analysis of the protein bands was performed using ImageJ. F, G) Representative images of degradation assays performed for the (F ) pro-and (G) anti-inflammatory cytokines, respectively. H ) CCL2/MCP-1 was directly cleaved by recombinant mMCP6 (red box in F indicates reduced intensity of the protein band) compared with the control conditions. I-M) However, IL-6, TNF-a, IL-1b, IL-4, and IL-10 were not cleaved by mMCP6 compared with the control conditions. Data are presented as means 6 SEM (expressed as percentage of control). L, molecular weight ladder. *P , 0.05, **P , 0.01, ***P , 0.001. mMCP6 (Fig. 7C, red box) . Similar results were observed when fibronectin was incubated with MC WT degranulate, which resulted in reduced intensity levels of the fibronectin protein band (Fig. 7D, green box) . This cleavage effect was significantly reduced when fibronectin was incubated with
MC mMCP6
2/2 degranulate. Additionally, collagen IV was cleaved after incubation with recombinant mMCP6 compared with the vehicle control group (Fig. 7E, green box) . Similar results were found after incubation with MC WT degranulate, which lead to a reduced expression of the 250 Distance from lesion center (μm x 100) Figure 3 . Increased lesion size and glial scarring response in MC-deficient mice after SCI. A) Representative images of the lesion size, astrogliosis, and CSPG-expression at the lesion area for WT (i, ii) and MC-deficient mice (iii, iv) at 28 dpi, respectively. Large asterisks in (A) indicate the lesion center. B) Lesion size was determined via image analysis of the GFAP-negative area [area marked by white line (Ai, ii)]. C ) Astrogliosis was quantified by measuring GFAP intensity, within square areas of 100 mm 3 100 mm (white boxes in Ai, ii), extending 600 mm cranial to 600 mm caudal from the lesion border. Image analysis revealed no difference in astrogliosis between WT mice (Ai) and MC-deficient mice (Aii). GFAP expression levels were lower caudally from the lesion site in both groups. D) Expression of chondroitin sulfate proteoglycans (CSPGs) was determined in the perilesional area (area marked by enclosed white line in Aiii, iv). A significant increase in CSPG intensity in the perilesional area was observed in MC-deficient mice (Aiv) compared with WT mice (Aiii) after injury. Scale bar, 500 mm. Data are presented as means 6 SEM. WT control mice: n = 12; MC-deficient mice: n = 6. The histologic analyses were performed on 1 representative experiment out of 3 independent experiments that were performed under the same conditions. *P , 0.05.
kDa protein band that corresponds with collagen IV (Fig. 7F ). This cleavage was reduced when collagen IV was incubated with MC mMCP6 2/2 degranulate. However, it is important to note that the intensity of the bands for collagen IV was low after a 48 h incubation period. Laminin is a trimeric protein with a molecular weight of ;800 kDa that consists of an a-chain . Increased expression of fibrous and basal lamina components at the lesion site in MC-deficient mice after a hemisection injury. A) Representative images of fibronectin, laminin, and collagen IV expression at the lesion center for WT and MC-deficient mice at 28 dpi. Immunofluorescence for fibronectin was performed to compare fibrous scarring at the lesion center between MCdeficient mice and their WT control mice after SCI. Large asterisks in A indicate lesion center. B) A larger fibronectin-positive scar area was observed in MC-deficient mice (Aii) compared with WT mice (Ai). E) In addition, image analysis revealed a significant increase in fibronectin intensity at the lesion center in MC-deficient mice. C-G) Expression of basal lamina components was compared between the 2 groups at the lesion center, using immunofluorescence for laminin and type IV collagen. A significant increase in both the scar area and intensity of laminin (C, F) and collagen IV (D, G) was observed in MC-deficient mice (Aiv, vi) compared with WT mice (Aiii, v). Data are presented as means 6 SEM. WT control mice: n = 12; MC-deficient mice: n = 6. The histologic analyses were performed on 1 representative experiment out of 3 independent experiments performed under the same conditions. Scale bar, 500 mm. *P , 0.05.
visible as 2 protein bands on a blot. No reduction in expression or cleavage of these laminin subunits was observed after incubation with recombinant mMCP6 compared with the controls (Fig. 7G) . In contrast, intensity of the 200 kDa protein band (green box) was significantly reduced after incubation with both MC WT and MC mMCP6 2/2 degranulate (Fig. 7H, green box) . However, no difference was observed between MC WT and MC mMCP6 2/2 degranulate, indicating that mMCP6 does not directly cleave laminin.
Increased gene expression of scar-associated factors in mMCP6 knockout mice
As a next step, we addressed the question whether endogenous mMCP6 influences the gene expression of several scar-associated markers after SCI. The expression of mMCP6 mRNA was significantly up-regulated at 2 dpi in WT mice compared with WT control mice (Fig. 8A) . No mMCP6 mRNA was detected in mMCP6 2/2 mice, which illustrates that these mice do not express mMCP6. Increased lesion size and glial scarring response in mMCP6 2/2 mice after a hemisection injury. A) Representative images of the lesion size, astrogliosis, and CSPG-expression at the lesion area for WT (i, ii) and mMCP6 2/2 mice (iii, iv) at 28 dpi, respectively. Large asterisks in (A) indicate the lesion center. B) Lesion size was determined via image analysis of the GFAPnegative area (area marked by white line in Ai, ii). A significant increase in lesion size was observed in mMCP6 2/2 mice (Aii) after SCI compared with WT control mice (Ai). C ) Image analysis revealed no difference in astrogliosis between WT control mice (Ai) and mMCP6 2/2 mice (Aii). GFAP intensity was lower caudally from the lesion site in both groups. D) Expression of CSPGs was determined in the perilesional area [area marked by enclosed white line (Aiii, iv)]. A significant increase in CSPG intensity was observed in the perilesional area in mMCP6 2/2 mice (Aiv) compared with control mice (Aiii). Data are shown as means 6
SEM. WT control mice: n = 10; mMCP6 2/2 mice: n = 8. The histologic analyses were performed on 1 representative experiment out of 2 independent experiments that were performed under the same conditions. Scale bar, 500 mm. *P , 0.05. Figure 6 . Increased expression of fibrous ECM and basal lamina components in mMCP6 2/2 mice after SCI. A) Representative images of fibronectin, laminin and collagen IV expression at the lesion center for WT and mMCP6 2/2 mice at 28 dpi. Immunofluorescence for fibronectin was performed to compare fibrous scarring between WT mice and mMCP6 2/2 after injury. Large asterisks in A indicate lesion center. B) A larger fibronectin-positive scar area was found in mMCP6
2/2 mice (Aii) compared with WT mice (Ai). E ) No difference in fibronectin intensity was observed at the lesion center between the 2 groups (Ai, ii). C-G) Expression of basal lamina components at the lesion center was also compared between the 2 groups, using immunofluorescence for laminin and type IV collagen. Both laminin scar area and intensity (C, F ) were significantly increased in mMCP6 2/2 mice (Aiv) compared with WT mice (Aiii). D) In addition, the collagen IV-positive scar area was larger in mMCP6 2/2 mice (Av, vi). G) No difference in collagen IV intensity was found between the 2 experimental groups (Av, vi). Data are presented as means 6 SEM. WT control mice: n = 10; mMCP6 2/2 mice: n = 8. The histologic analyses were performed on 1 representative experiment out of 2 independent experiments performed under the same conditions. Scale bar, 500 mm. *P , 0.05; **P , 0.01; ***P , 0.001. Quantitative PCR analysis showed that GFAP mRNA levels increased immediately after injury in both WT and mMCP6 2/2 mice. At 2 dpi, these expression levels were significantly higher in WT mice (fold change in expression vs. WT control condition; 1.833 6 0.124) compared with mMCP6 2/2 mice (0.905 6 0.202) (Fig. 8B) . GFAP mRNA levels remained elevated in both groups after injury until the end of the observation period. We also determined the gene expression profiles of selected CSPGs that exert axongrowth inhibitory effects in SCI, namely aggrecan, neurocan, and brevican ( Fig. 8C-E) . Aggrecan mRNA levels were significantly increased in mMCP6 2/2 mice (2.073 6 0.330) compared with WT mice (1.078 6 0.175) at 7 dpi (Fig. 8C) . Neurocan mRNA levels increased after injury, but they were comparable in mMCP6 2/2 and WT mice (Fig. 8D) . In contrast, brevican mRNA levels were decreased after SCI and no difference was observed between the 2 groups (Fig. 8E) . Fibronectin mRNA levels were also increased after injury and this was significantly higher in mMCP6 2/2 mice (15.178 6 1.275) compared with WT mice (8.347 6 1.152) at 7 dpi (Fig. 8F) . In addition, expression levels of the basal lamina components (i.e., laminin and collagen IV) were also elevated immediately after injury (Fig. 8G, H) . We did not observe any difference in laminin mRNA expression between the 2 experimental groups (Fig. 8G ), but at 7 dpi, collagen IV mRNA levels were significantly higher in mMCP6 2/2 mice (14.169 6 1.107) compared with WT mice (8.018 6 0.634) (Fig. 8H) .
DISCUSSION
Increasing evidence indicates that MCs protect the CNS after mechanical damage (26, 27) . They may temper detrimental inflammatory processes after injury by degrading local proinflammatory cytokines, mediated via an MCspecific chymase (mMCP4) released from their granules (27) . In the present study, we demonstrate that mMCP6, the most prominent protease secreted by connective tissuetype MCs, supports functional recovery after SCI. Similar to mMCP4, deficiency in mMCP6 leads to reduced locomotory functions after SCI. Surprisingly, most inflammationassociated mMCP4 substrates are not degraded by mMCP6 and their levels are not elevated in mMCP6 knockout mice, suggesting a different mechanism of how mMCP6 may exert beneficial effects after SCI.
We demonstrate here that MCs improve functional recovery after SCI by modulating the inhibitory scar that is formed at the lesion site. Furthermore, we show that these scar-remodeling effects are, at least in part, mediated via mMCP6. We investigated the effect of MCs and mMCP6 on scarring in an in vivo model of SCI. We decided to use a well-established model of a T-cut hemisection injury, which produced a standardized lesion (37, 49) . Functional recovery was significantly impaired in MC-deficient Kit W-sh/W-sh mice as well as in mMCP6 knockout mice after a SCI. This decline in motor function was associated with a significantly increased lesion size and a substantially more pronounced scarring response. We focused on 4 key components of the scar that accumulate at the lesion site after SCI and inhibit axon growth: CSPGs in the perilesional area (5, 7) and fibronectin, laminin, and collagen IV in the fibrous as well as a basement membrane-rich compartment at the lesion center (9, 14, 48) . Expression levels of axon-growth inhibitory CSPGs were significantly increased in the perilesional area in MC-deficient and mMCP6
2/2 mice after injury. CSPGs are strongly expressed after a traumatic CNS injury and they inhibit axon growth and plasticity (50) (51) (52) . Consistently, the enzymatic degradation of CSPGs improves axon regeneration and recovery after injury in vivo (6, 53, 54) . Hence, the impaired functional recovery observed in MCdeficient and mMCP6 2/2 mice may be related to the increased levels of CSPGs that are expressed at the injury site in these mice. In addition, we found a strong up-regulation of fibrous ECM and basal membrane components in the absence of MCs or mMCP6 following SCI. Similar to CSPGs, this fibrous scar is considered as a major impediment for recovery processes after injury in vivo (55, 56) . Damaged axons initiate a regenerative response after injury, but they stop growing when they encounter the border of the fibrotic scar and fail to traverse it (14) . Moreover, elimination of fibrotic scar components promotes regeneration of injured axons and improves functional recovery after CNS injury (13, 56) . Taken together, we showed here by using MC-deficient and mMCP6 2/2 mice that MCs support recovery after SCI via mMCP6-induced scar remodeling. When interpreting these data, one must keep in mind that not all effects seen in Kit W-sh/W-sh may be a result of MC-deficiency, because some Kit effects appear to be independent of MCs (57) . Furthermore, the complete lack of a molecule in a mouse strain could activate specific compensatory mechanisms or may cause additional defects. A complementary approach to study MC-specific functions in vivo is the use of Cre-Master mice (57) . In this mouse model, MCs are eradicated via Cre-recombinase in a Kit-independent manner. Unfortunately, these mice are not commercially available.
To confirm our findings, it would be ideal to perform MC reconstitution experiments with either WT or mMCP6 2/2 bone marrow-derived MCs to confirm that phenotypes in these knockout mice are truly MC-or mMCP6-dependent (58, 59) . MC reconstitutions have been successfully used before in non-CNS models (60) . Unfortunately, extensive pilot experiments in our laboratory revealed that MC reconstitution only leads to a was determined by SDS-PAGE and Western blot analysis. A, B) No cleavage of CSPGs was observed after incubation with recombinant mMCP6 or with MC degranulate. C ) Fibronectin was directly cleaved by recombinant mMCP6 (red box indicates cleavage fragments). D) Similar results were found following incubation with MC WT degranulate, whereas MC mMCP6 2/2 degranulate was not able to cleave fibronectin. E ) Collagen IV was directly cleaved by recombinant mMCP6 (red box indicates cleavage fragments). F ) Similar results were found after incubation with MC WT degranulate, whereas incubation with MC mMCP6 2/2 degranulate did not result in cleavage of collagen IV. G) Laminin was not cleaved after incubation with recombinant mMCP6; however, (H ) laminin was degraded following incubation with both MC WT and MC mMCP6 2/2 degranulate. n = 3-4/condition. Data are shown as means 6 SEM (expressed as percentage of control). *P , 0.05, **P , 0.01, ***P , 0.001. partial redistribution of MCs in the meninges, but not in the CNS parenchyma (Kramer and Hendrix, unpublished observation). Similarly, in a study using green fluorescent protein-expressing bone marrow cultured MCs for reconstitution in MC-deficient Kit W/W-v mice, MC populations were not restored in brain and spinal cord (61) . Therefore, in our opinion, reconstitution experiments are not ideal to distinguish between MCdependent and independent effects in the CNS [see review (22) for details]. Several studies in other experimental models such as rheumatoid arthritis and tumor angiogenesis indicate that MC tryptase degrades ECM factors in vivo, either directly or indirectly by activating other ECM-remodeling proteases (34, 62, 63) . Our in vitro degradation assays show direct cleavage of fibronectin and collagen IV by recombinant mMCP6, indicating that these ECM components are substrates of this MC protease. These data were supported by others, which demonstrate that MC tryptase has potent gelatin degrading properties and that it cleaves collagen IV and fibronectin (33, 64, 65) . In contrast, mMCP6 does not directly cleave CSPGs and laminin in vitro, although the levels of these 2 components were increased at the lesion site after injury in mMCP6 2/2 mice. This may indicate that mMCP6 indirectly participates in the cleavage of these components by activating other proteases in vivo. Alternatively, there is increasing evidence that human b-tryptase has not only the classic functions of a protease, but may also act as a Expression levels of (A) mMCP6 and of the glial scar-associated genes (B) GFAP, (C ) aggrecan, (D) neurocan, (E ) brevican, (F ) fibronectin, (G) laminin, and (H ) collagen IV were measured by quantitative PCR analysis in spinal cord tissue from WT (white circles) and mMCP6 2/2 mice (black circles) at 2 dpi, 7 dpi, and 28 dpi. As a control, samples from mice that did not undergo surgery were included. The expression levels of mMCP6 (A) were significantly up-regulated at 2 dpi, and no expression of mMCP6 mRNA was detectable in mMCP6 2/2 mice. GFAP (B) mRNA levels were significantly elevated in WT mice compared with mMCP6 2/2 mice at 2 dpi. In contrast, aggrecan (C ), fibronectin (F ), and collagen IV (H ) mRNA levels were significantly higher in mMCP6 2/2 mice at 7 dpi. Expression levels were normalized to the reference genes YHWAZ, CYCA, and HMBS and converted to fold change values vs. the WT control condition using the 2 2DDCT method. n = 326/group. YHWAZ, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein z. ***P , 0.001, compared with mMCP6 2/2 mice; # P , 0.05, compared with WT control mice. potent regulator of gene expression (66) (67) (68) . Therefore, we analyzed the gene expression profiles of the glial scarassociated genes GFAP, fibronectin, laminin, and collagen IV in spinal cord tissue from WT and mMCP6 2/2 mice at several time points after injury. Because CSPGs are a heterogeneous group of several proteoglycans, we determined the gene expression profiles of selected CSPGs that exert axon-growth inhibitory effects in SCI, namely aggrecan, neurocan, and brevican (7). We found a significant up-regulation of collagen IV and fibronectin mRNA levels in the injured spinal cord of mMCP6 2/2 mice. Additionally, aggrecan gene expression was also significantly up-regulated in mMCP6 2/2 mice after injury. Thus, we provide first suggestive evidence that endogenous mMCP6 may directly or indirectly suppress the gene expression of several scar-associated ECM components after SCI. Previously, it has been shown that MC tryptase can affect gene expression via cleavage of the protease activated receptor-2, a member of the G-protein-coupled receptor family (67, 69) . Apart from this direct effect, it is also possible that mMCP6 indirectly influences gene expression by cleaving other substrates. However, further studies are needed to reveal which gene regulatory mechanism of mMCP6 are involved in CNS injury and regeneration.
Apart from the scar remodeling properties, mMCP6 is also known as a potent inflammatory mediator, and it may affect several inflammatory processes in vivo (30, 70) . We therefore investigated the effect of mMCP6 on inflammatory components (i.e., cytokines and chemokines) that play a key role on axon regeneration and other recovery processes after CNS trauma (45) (46) (47) , by performing in vitro degradation assays and by comparing spinal cord cytokine/chemokine levels between WT and mMCP6 2/2 mice in the acute-subacute phase after SCI. Surprisingly, our data indicate that none of the investigated cytokines are a substrate of mMCP6 except CCL2/MCP-1. Previous in vitro studies (71) suggested that IL-6 may be a substrate of mMCP6 but our in vitro and in vivo data could not corroborate these findings. In summary, our in vivo data suggest that mMCP6 has no substantial influence on key inflammatory factors after SCI -in striking contrast to mMCP4 (27) .
In conclusion, we provide evidence that MCs and their secreted protease mMCP6 have a beneficial role in SCI by targeting the inhibitory scar via 2 mechanisms: 1) direct or indirect cleavage of inhibitory scar components and 2) alteration of the gene expression of these scar factors after injury. Until now, no effective clinical treatment exists that can restore lost functions after SCI (1, 72) . Our findings highlight mMCP6 as a new endogenous factor that improves spontaneous recovery and may therefore be considered as a promising therapeutic tool for the treatment of SCI. Previously, we showed that mMCP4 promotes recovery after CNS injury by degrading proinflammatory mediators (26, 27) . Thus, mMCP4 and mMCP6 support recovery after SCI via different but interrelated mechanisms. Increasing evidence indicates that there is a strong interplay between inflammatory processes and the scarring response after CNS injury (73, 74) . It is therefore tempting to speculate that a combination of both factors has synergistic effects, and a combination therapy for SCI with mMCP4 and mMCP6 may be very promising. The next steps will be the therapeutic application of these proteases, either alone or in combination, in rodents and later in primates to test the translational significance.
